TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Lexaria Bioscience ( (LEXX) ).
Lexaria Bioscience has achieved a significant milestone in its Phase 1b GLP-1 study in Australia, completing the last patient visit. The study, which involves various DehydraTECH formulations, aims to assess the safety and efficacy of these formulations compared to traditional semaglutide treatments. The company is currently analyzing data, with final results expected by late 2025. This progress could position Lexaria as a leader in oral drug delivery, potentially impacting the treatment of diabetes and obesity by offering alternatives to injectable medications.
The most recent analyst rating on (LEXX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, primarily focusing on its patented DehydraTECH technology. This platform enhances the bio-absorption of drugs through oral delivery, aiming to improve drug efficacy and reduce side effects.
Average Trading Volume: 144,495
Technical Sentiment Signal: Sell
Current Market Cap: $16.3M
Find detailed analytics on LEXX stock on TipRanks’ Stock Analysis page.